CIPLA Cipla Q2 FY27 results (Jul–Sep 2026) and concall
Cipla reported Q2 FY27 revenue of ₹7,404 crores (+4% QoQ). EBITDA margin rose 200bps sequentially to 18.7% and PAT was ₹878 crores. One India was the main driver, posting record revenue and 12% YoY growth with GLP-1 (Yurpeak) and chronic therapies leading. North America rose to $172 million. Management kept its FY27 guidance of a $1 billion annualized U.S. exit run rate and an 18.5–20% EBITDA margin, which rests on ramping up Ventolin and Advair supply from the new U.S. plant and on 3 pending approvals (2 respiratory, 1 peptide). With ₹9,823 crores of net cash, Cipla is adding to its biosimila
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY27: revenue down 2.4%, net profit down 37.0% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 7,073 | 6,730 | 6,957 | 7,589 | 7,074 +0% | 6,541 −3% | 7,119 +2% | 7,404 −2% |
| EBITDA | 1,989 | 1,538 | 1,778 | 1,895 | 1,255 −37% | 955 −38% | 1,192 −33% | 1,388 −27% |
| Net profit | 1,575 | 1,214 | 1,292 | 1,353 | 674 −57% | 543 −55% | 786 −39% | 852 −37% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
